Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 02:09:24 - browse：2

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Gene therapy has helped boys walk. Can scientists keep it that way?

entertainment

WSS

3 hurdles to bringing medical devices to the U.S. market

With FDA staff opposed to Sarepta therapy, top official intervened

How redistricting in 6 states could affect who controls Congress

What to know about a major upcoming Wegovy heart health study

What to know about a major upcoming Wegovy heart health study

The strategy behind pharma's lawsuits over drug pricing reform

entertainment

Wikipedia

explore

Supreme Court strikes down use of affirmative action

How redistricting in 6 states could affect who controls Congress

New air purifier tech could be key to improving indoor air quality

How corporate America is slashing DEI workers amid backlash to diversity programs

In age of alternative facts, a scholarly course on calling out crap

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Trump demands the U.S. pay no more for drugs than other countries … again

With FDA staff opposed to Sarepta therapy, top official intervened

Drug repurposing or repositioning? The language matters

Disclosing genetic information: not as worrisome as once feared

entertainment

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Rare Northern Lights show in US this week: Where and how to see it

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

#NeedHerScience: shining a light on gender disparities in medicine

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

FDA approves Leqembi, a milestone in Alzheimer’s treatment

focus

entertainment

entertainment

leisure time